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pathway involving FGF21. GLP-1 therapy
also activated the iNKT-FGF21 axis,
which contributes to weight loss.
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Adipose-resident invariant natural killer T (iNKT) cells
are key players inmetabolic regulation. iNKT cells are
innate lipid sensors, and their activation, using their
prototypic ligand a-galactosylceramide (aGalCer),
induces weight loss and restores glycemic control
in obesity. Here, iNKT activation induced fibroblast
growth factor 21 (FGF21) production and thermo-
genic browning of white fat. Complete metabolic
analysis revealed that iNKT cell activation induced
increased body temperature, V02, VC02, and fatty
acid oxidation, without affecting food intake or ac-
tivity. FGF21 induction played a major role in
iNKT cell-induced weight loss, as FGF21 null mice
lost significantly less weight after aGalCer treat-
ment. The glucagon-like peptide 1 (GLP-1) receptor
agonist, liraglutide, also activated iNKT cells in hu-
mans and mice. In iNKT-deficient mice, liraglutide
promoted satiety but failed to induce FGF21, result-
ing in less weight loss. These findings reveal an
iNKT cell-FGF21 axis that defines a new immune-
mediated pathway that could be targeted for glyce-
mic control and weight regulation.
INTRODUCTION
Obesity threatens to shorten the human lifespan by 5–20 years,
the biggest burden being obesity-induced diseases (Wang
et al., 2011). Obesity is far more complex and touches many
more aspects of biology than was previously appreciated.
Currently, therapy for obesity is limited by an incomplete
understanding of how body weight is controlled. A promising
potential approach for treating obesity is activation of brown
adipose tissue (BAT). In contrast to energy-storing white adi-510 Cell Metabolism 24, 510–519, September 13, 2016 ª 2016 Elsevpose tissue (WAT), BAT contains many thermogenic mito-
chondria that express uncoupling protein 1 (UCP-1), which
dissipates chemical energy into heat (Enerba¨ck et al., 1997).
Recently, it was shown that multi-locular adipocytes expressing
UCP-1 can also be induced in WAT, known as beige or brite
cells (Cousin et al., 1992; Enerba¨ck, 2009). Browning of WAT
uses large amounts of energy through induction of b-oxidation,
resulting in increased metabolic rate and weight loss. Chronic
cold exposure and b-adrenergic stimulation are physiological
inducers of browning in WAT (Cousin et al., 1992; Himms-Ha-
gen et al., 1994). More recently, the hormone fibroblast growth
factor 21 (FGF21), produced in liver, WAT, and BAT, was
shown to improve metabolic disease and induce weight loss
in humans and mice (Gaich et al., 2013; Hanssen et al., 2015;
Kharitonenkov and Adams, 2013; Kharitonenkov et al., 2005;
Samms et al., 2015). Recently, a synthetic FGF21 variant,
LY2405319, was shown to reduce low-density lipoprotein
(LDL) cholesterol and triglycerides, increase adiponectin levels,
improve fasting insulin, and induce weight loss in obese pa-
tients with type 2 diabetes (Gaich et al., 2013). FGF21 admin-
istration has been associated with increased UCP-1 levels,
which are required for FGF21-induced thermogenesis; how-
ever, FGF21 reduces food intake, contributing to weight loss,
independently of UCP-1 (Samms et al., 2015). These studies
position FGF21 as a promising drug target for the treatment
of metabolic disorders.
Recent studies have highlighted a role for the innate immune
system in activation of BAT and induction of browning in WAT.
Alternatively activated macrophages can produce catechol-
amines in response to cold exposure, which activates BAT and
induces lipolysis inWAT (Nguyen et al., 2011). Eosinophils, which
secrete IL-4 and IL-13, sustain alternative macrophage activa-
tion and catecholamine production in cold settings (Qiu et al.,
2014). Independent of cold exposure, cytokines including IL-33
are critical for maintaining innate lymphoid cells (ILCs) in adipose
tissue, which are key players in regulating energy expenditure
(Molofsky et al., 2013). ILCs can also induce browning by pro-
ducing methionine-enkephalin, which upregulates UCP1+ beigeier Inc.
Figure 1. Activation of iNKT Cells Induces Weight Loss through Thermogenesis
(A) Body weight of obese WT mice 4 days after one injection of 1 mg/mouse (n = 15 per group) (left) or 2 mg/mouse (n = 10 per group) (right) aGalCer or vehicle
control.
(B) Change in body weight after aGalCer or vehicle control.
(legend continued on next page)
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adipocytes in WAT (Brestoff et al., 2015). Thus, recent studies
have solidified the role of the adipose innate immune system in
the regulation of metabolism and body weight.
Invariant natural killer T (iNKT) cells are one such innate im-
mune cell type with an important role in weight and glycemic
control. iNKT cells are activated by lipid antigens presented by
CD1d molecules (Brigl and Brenner, 2004). We and others
have shown that iNKT cells are enriched in human and murine
adipose tissue (Lynch et al., 2009, 2012), and that iNKT cells
can regulate body weight and restore metabolic homeostasis
in obesity (Hams et al., 2013; Huh et al., 2013; Ji et al., 2012;
Lynch et al., 2012; Schipper et al., 2012). Recently, we found
that adipose iNKT cells are a unique regulatory subset of iNKT
cells with a distinct gene expression profile and anti-inflamma-
tory functions (Lynch et al., 2015). Adipose iNKT cells are
reduced in obesity, but activating iNKT cells with their prototyp-
ical lipid ligand a-galactosylceramide (aGalCer) causes their
expansion, which induces potent weight loss; however, the
weight loss mechanism is not understood. Here, we report that
iNKT cell-induced weight loss occurs through browning of
WAT and thermogenesis, without loss of appetite. Furthermore,
FGF21 induction is a key player in this weight loss pathway. This
iNKT-FGF21 pathway plays a physiological role in a subset of the
actions of glucagon-like peptide 1 (GLP-1), a gut hormone that
controls glycemia and satiety (Turton et al., 1996), leading to
weight loss (Baggio and Drucker, 2007). In rodents, GLP-1 also
regulates body temperature (O’Shea et al., 1996) and activates
pathways associated with increased numbers of thermogenic
beige and brown adipocytes (Lockie et al., 2012). Here, we
show that murine iNKT cells contribute to the weight loss ef-
fects observed with administration of GLP-1 receptor (GLP-1R)
agonists.
RESULTS AND DISCUSSION
To investigate the mechanism of iNKT cell-induced weight loss,
we specifically activated iNKT cells in obese mice by using their
lipid antigen ligand aGalCer. A single intraperitoneal (i.p.) injec-
tion of aGalCer potently induced weight loss in obese mice (Fig-
ures 1A and 1B). The effects of aGalCer were dose dependent;
1 mg aGalCer induced an average of 2.5 g of body weight in
obese mice on high-fat diet (HFD) for 6–12 weeks (n = 15) (Fig-
ures 1A and 1B; p % 0.0001), while mice fed an HFD of longer(C) Flow plots of iNKT cells, measured by aGalCer-loaded CD1d tetramer+ cells in
show percent of CD45+ cells (top) and percent of T cells (bottom).
(D) Change in epididymal (n = 15 per group), subcutaneous (n = 10 per group), and
treatment.
(E) Body weight of obese WT mice 3 days after one injection of vehicle and then
(F andG) (F) O2 consumption and (G) CO2 production in obeseWTmice acclimatize
3 days. Each mouse served as its own control (n = 6). Results displayed in 12 hr
(H) Body temperature measured by implanted peritoneal temperature probes.
(I) Infrared images and graph showing body temperature of obese WT mice 48 h
(J) RER of obese WT mice treated with vehicle control for 3 days (blue) or aGalC
(K) Calculation of energy expenditure in the first and second 24 hr period followin
weight.
In (J) and (K), n = 6 per group.
(L) Fasting blood glucose 4 days post-vehicle or 1 mg aGalCer treatment (n = 5–6
mean (± SEM).
Statistics have been calculated using a Student’s paired t test (A and E) and unp
512 Cell Metabolism 24, 510–519, September 13, 2016duration (16–20 weeks) received 2 mg aGalCer and lost signifi-
cantly more body weight (3.7 g lost with aGalCer, n = 10; versus
0.3 g increase with vehicle control, n = 10). We have previously
shown that aGalCer reduces the percentage of fat mass, but
not lean mass, in mice as measured by dual X-ray absorptiome-
try (DEXA) (Lynch et al., 2012). The reduction in total body fat
after aGalCer prompted us to look at other fat depots in addition
to epididymal fat pads. We found that iNKT cells are enriched in
all adipose depots examined compared to spleen, except omen-
tum, which contained fewer iNKT cells (Figure 1C). aGalCer acti-
vated iNKT cells in all adipose depots (as measured by iNKT cell
expansion >3-fold and CD69 upregulation; data not shown) and
induced a significant decrease in fat padmass in the epididymal,
subcutaneous, and perirenal adipose depots (Figure 1D). Thus,
specific aGalCer activation of iNKT cells induces potent body
weight loss associated with a reduction in the fat mass of several
fat depots.
To understand how iNKT cell activation induces a rapid
reduction of 10% of body weight in 4 days, we measured
whole-body metabolism using Complete Lab Animal Monitoring
System (CLAMS). Obese mice (n = 6) were placed in the CLAMS
and served as their own controls: they were first acclimatized
and then received vehicle control (1 mg), metabolic readouts
were measured for 70 hr, and then they received 1 mg aGalCer
treatment and remained in the chambers for 70 hr. As before,
mice lost significant weight after aGalCer treatment, but not
vehicle control. Unlike control-treated mice, a single aGalCer
injection induced an increase in VO2 and VCO2 (Figures 1F and
1G). There was a slight, but not significant, reduction in locomo-
tor activity after aGalCer treatment, and despite weight loss,
there was no reduction in daily food intake (Figures S1A and
S1B, available online). aGalCer treatment induced a robust and
consistent increase in thermogenesis (Figure 1H). To confirm
this increase in thermogenesis, we performed a separate exper-
iment where obese mice received vehicle (n = 5) or aGalCer
(n = 5), and body temperature was visualized using a forward-
looking infrared (FLIR) camera, showing that aGalCer treatment
induced a 1 rise in body temperature (Figure 1I). Most strikingly,
aGalCer induced a significant decrease in the respiratory ex-
change ratio (RER) (Figure 1J), which is a measurement of sub-
strate utilization. Decreased RER shows preferential burning of
fat, rather than carbohydrates, as the main source of energy,
indicating induction of b-oxidation. After adjusting for foodvarious adipose depots and spleen, representing five individual mice. Numbers
perirenal (n = 5 per group) fat pad size in obese WTmice 4 days post-aGalCer
3 days after 1 mg aGalCer, following CLAMS experiment (n = 6 per treatment).
d inmetabolic cages, then treatedwith vehicle for 3 days, and then aGalCer for
periods (shaded area represents the dark cycle).
r after receiving aGalCer (1 mg) or vehicle (n = 5 per treatment).
er for 3 days (red).
g treatment with vehicle or aGalCer after adjustment for food intake and body
per group, two independent experiments). Small horizontal bars indicate the
aired t test (B, D, I, K, and L). *p < 0.05, **p < 0.01, ***p < 0.001.
intake and body weight of each mouse, energy expenditure cal-
culations showed that one aGalCer treatment induced signifi-
cantly higher energy expenditure in mice in each 24 hr period
following treatment (Figure 1K). In addition to the weight loss,
we confirmed our previous finding (Lynch et al., 2012) that
aGalCer activation of iNKT cells in obese mice also improves
fasting glucose levels (Figure 1L). This striking change in meta-
bolic rate and energy homeostasis would explain the potent
effects on weight loss seen with aGalCer treatment.
The induction of b-oxidation, thermogenesis, and reduced
WAT suggested that activation of browning of WAT may have
occurred. Consistent with this possibility, we found significant in-
duction of UCP1+ cells in inguinal WAT within 24 hr after aGalCer
(Figure 2A). Cold temperatures and b-adrenergic stimulators are
physiological activators of browning in WAT. As mice treated
with aGalCer were housed at room temperature where full BAT
activation is not required, we investigated iNKT-dependent
mechanisms leading to browning of WAT. FGF21 has been
shown to improve metabolic disorders and induce weight loss
in humans and mice (Kharitonenkov and Adams, 2013). FGF21
has been implicated in inducing a thermogenic program in
WAT through activation of PGC1a (Fisher et al., 2012), as well
as by induction of adiponectin, leading to increased energy
expenditure (Holland et al., 2013). Administration of aGalCer
strongly induced FGF21 transcripts in inguinal adipose tissue
within 3 hr of administration, to a similar extent as the b3-adre-
noreceptor agonist CL316,243 (Figure 2B). At 3 hr after aGalCer,
FGF21was not activated in BAT; however, by 24 hr after aGalCer
treatment, FGF21 transcripts were also significantly induced in
BAT and further increased in inguinal adipose tissue (Figures
2B and 2C). In contrast, FGF21 expression was not induced in
WAT or BAT of CD1d/ (iNKT deficient) mice after aGalCer,
confirming an iNKT-dependent effect (Figure 2C). FGF21 protein
secretion was also significantly increased from explants of
inguinal WAT and BAT after aGalCer treatment (Figure 2D).
Furthermore, serum FGF21 levels were significantly elevated af-
ter aGalCer treatment, at even higher levels than those detected
after administration of CL316,243 (Figure 2E). Surprisingly,
despite the liver being another key source of iNKT cells and
FGF21, aGalCer treatment did not increase FGF21 levels in liver
(Figure S1C). aGalCer also induced adiponectin in inguinal adi-
pose tissue of wild-type (WT), but not in CD1d/, mice (Fig-
ure 2F). Although aGalCer is a specific activator of iNKT cells
and is not a b-adrenoreceptor agonist, we assessed if iNKT cells
could induce FGF21 without aGalCer activation. To examine
this, we adoptively transferred iNKT cells into obese CD1d/
mice (in vivo), and in another experiment, we co-cultured iNKT
cells with obese adipose tissue (in vitro). In both types of exper-
iments, iNKT cells increased levels of FGF21 protein, and adipo-
nectin in adipose tissue (Figure 2G). Thus, our data show that
iNKT activation or adoptive transfer induces FGF21, thermogen-
esis, and weight loss, implicating FGF21 as an important medi-
ator of this pathway. To examine if FGF21 was required for
iNKT-mediated weight loss, we investigated FGF21 null mice.
FGF21/ mice were fed an HFD for 12 weeks and treated with
aGalCer or vehicle control. In the absence of FGF21, aGalCer-
induced weight loss was significantly attenuated, compared to
WT controls (Figure 2H). There was no statistical difference in
themeanweight of the epididymal fat pads between groups (Fig-ure 2I). Thus, iNKT cell activation or adoptive transfer in-
duces FGF21, adiponectin, b-oxidation, browning of WAT, and
increased energy expenditure leading to weight loss, which is
partly dependent on induction of FGF21.
Discovery of an iNKT-FGF21 thermogenic pathway led us to
question if this pathway was physiologically relevant in other
weight loss settings. As we have previously shown that liraglu-
tide and native GLP-1 can activate human iNKT cells (Hogan
et al., 2011), and GLP-1 receptor signaling can regulate
lymphocyte maintenance and proliferation (Hadjiyanni et al.,
2010), we examined whether GLP-1R signaling-induced weight
loss was dependent in part on iNKT cell activation. Obese mice
fed an HFD for 8 weeks were treated with the GLP-1R agonist
liraglutide or PBS control by i.p. injection daily for 5 days.
As expected, liraglutide treatment lowered fasting glucose,
improved glucose handling (Figure S2A), reduced body weight
and epididymal fat pad weight (Figures S2B and S2C), and
decreased adipocyte size (Figure S2D). Consistent with our
previous finding in humans, liraglutide increased iNKT cell
frequency in blood and adipose tissue (Figures 3A and 3B). Ad-
ipose iNKT cells were activated by liraglutide treatment, evi-
denced by an increased expression of the activation marker
CD69 in vivo (Figure 3C). Liraglutide also led to proliferation
of adipose iNKT cells (Figure S2E) and increased their IL-10
production in vivo (Figure 3D), a hallmark of adipose iNKT cell
regulatory function (Lynch et al., 2015). Furthermore, when
tested in vitro, liraglutide directly induced proliferation in murine
iNKT cell primary lines (Figure S2F) and induced their IL-10
production (Figures S2G and S2H). These results show that
the GLP-1 analog liraglutide can activate iNKT cells in vivo
and directly in vitro.
As liraglutide activates iNKT cells, and both liraglutide (Lovshin
and Drucker, 2009) and iNKT cell activation can promote weight
loss (Lynch et al., 2012), we determined whether GLP-1-iNKT
cell interactions were relevant to the metabolic and weight loss
effects of liraglutide GLP-1-based therapy. We fed WT and
CD1d/ mice (lacking iNKT cells) an HFD for 8 weeks and
treated them with liraglutide. The absence of iNKT cells did not
impact the glycemic effects of liraglutide (Figures 3E and 3F),
for liraglutide induces similar reductions in fasting glucose and
glycemic excursion in both WT and CD1d/ mice. However,
the presence of iNKT cells was required for the full weight loss
effects after several days of liraglutide administration; CD1d/
mice lost approximately one-third less overall weight than WT
mice after liraglutide treatment (Figure 3G). Although liraglutide
produced a significant reduction in food intake in both WT and
CD1d/ (Figure S2I), CD1d/ mice regained their weight and
exhibited no weight loss between days 2 and 6 following liraglu-
tide treatment, unlike WT mice, which continued to lose weight
(Figures 3H and 3I). Similar findings (less weight loss with liraglu-
tide) were seen in Ja18/mice on HFD, a second murine model
that lacks iNKT cells due to deletion of the invariant Ja18 T cell
receptor chain (Figure S3). Ja18/ mice and WT mice lost
similar weight in the first 24 hr, when food intake is severely
reduced, but following this initial 24 hr period, WT continued to
lose weight while Ja18/ gained weight (Figures S3B–S3D).
To rule out a central defect in GLP-1R signaling as a mechanism
for resistance to liraglutide-induced weight loss, we found that
GLP1r expression in the hypothalamus was similar in WT andCell Metabolism 24, 510–519, September 13, 2016 513
Figure 2. Activation of iNKT Cells Induces Browning of WAT, Partially through Induction of FGF21
(A) Immunohistochemical staining of UCP-1 protein in inguinal adipose tissue after vehicle control or aGalCer injection (representing one experiment with n = 4 per
group, repeated twice).
(B and C) qPCR for FGF21 transcript in inguinal adipose tissue and brown adipose tissue (BAT) at (B) 3 hr or (C) 24 hr after vehicle (n = 7) or aGalCer treatment
(n = 7), compared to b-adrenergic receptor agonist CL316,243 (1 mg/kg intraperitoneally) (n = 4) as a positive control (AU, arbitrary units).
(D) FGF21 protein level in supernatant of cultured ex vivo inguinal and brown adipose tissue, measured by ELISA, frommice treated in vivo with vehicle control or
aGalCer (n = 5 per group).
(E) Serum concentration of FGF21 after aGalCer or CL316,243, in WT and CD1d/ mice measured by ELISA (n = 5 per group).
(F) Adiponectin protein in inguinal adipose tissue after aGalCer or CL316,243, in WT and CD1d/ mice measured by ELISA (n = 3 per group, repeated twice).
(G) WT obese mice received iNKT cell adoptive transfer intraperitoneally, and 2 days later, adipose tissue was cultured overnight. In another experiment, obese
adipose tissue was co-culturedwith isolated adipose iNKT cells (in vitro). Supernatant was collected from both experiments, and FGF21 and adiponectin proteins
were measured (n = 4–5 per group).
(H and I) (H) Body weights and (I) epididymal fat pad weight of HFD-fed FGF21/mice (n = 6) andWTmice (n = 6) 3 days after one i.p. injection of 2 mg aGalCer or
vehicle. Graphs show the mean (± SEM).
Statistics have been calculated using a Student’s unpaired t test or ANOVAwith Tukey post hoc test for groups of three or more. *p < 0.05, **p < 0.01, ***p < 0.001.iNKT-deficient mice (CD1d/) (Figures S3E and S3F). CLAMS
studies revealed that CD1d/ mice had a lower metabolic rate
than WT mice (Figures S4A and S4B), consistent with the in-514 Cell Metabolism 24, 510–519, September 13, 2016crease in adiposity previously described (Lynch et al., 2012).
Liraglutide induced a slight decrease in overall VO2 and VCO2
in both WT and CD1d/ mice (Figures S4A and S4B), in
(legend on next page)
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agreement with reports that liraglutide-induced weight loss
mainly reflects reduced appetite and energy intake (Harder
et al., 2004; O’Shea et al., 1996; van Can et al., 2014). Neverthe-
less, central GLP-1R signaling can also induce thermogenesis
through activation of BAT, whichmay account for a small propor-
tion of liraglutide weight loss effects (Lockie et al., 2012). Thus,
we investigated if i.p. liraglutide treatment induced browning of
white inguinal fat. Liraglutide induced a robust thermogenic
gene expression program in WT mice, including upregulation
of UCP-1, PGC1a, and Cidea (Figure 3J). Importantly, this
response was blunted or lost in CD1d/ mice (Figure 3J). Lira-
glutide administered intraperitoneally did not induce a significant
change in thermogenic genes in BAT, although a trend was seen
in WT, but not CD1d/, mice (Figure S4C). Together, our find-
ings show (1) liraglutide activates iNKT cells, (2) iNKT cells are
required for the thermogenic program inWAT induced by liraglu-
tide, and (3) iNKT activation induces FGF21. Previous reports
have linked GLP-1 analogs with increased FGF21 expression
(Nonogaki et al., 2014; Yang et al., 2012). Thus, we examined
whether iNKT cells were required for the induction of FGF21 by
liraglutide. Liraglutide robustly induced FGF21 expression in
WT inguinal adipose tissue; however, FGF21 was not induced
in mice lacking iNKT cells (Figure 3K). Liraglutide also induced
expression of FGF21 receptors FGFR and b-klotho in adipose
tissue of WT, but not in CD1d/, mice (Figure 3L). Adiponectin,
a downstream regulator of FGF21 signaling, was also robustly
induced in adipose tissue by liraglutide in WT, but not iNKT,
cell-deficient mice (Figure 3M). Thus, although the primary
mechanism of action for the weight loss effects of liraglutide is
a reduction of energy intake, liraglutide also induces adiponec-
tin, FGF21, and an adipose thermogenic program that requires
a functional iNKT cell system.
Previously, we have shown that liraglutide can activate hu-
man iNKT cells in vitro (Hogan et al., 2011) and can increase
levels of circulating adiponectin in obese individuals with type
2 diabetes (Hogan et al., 2014). To ascertain the existence of
a GLP-1-iNKT cell-FGF21 axis in humans, we studied a cohort
of nine newly diagnosed obese type 2 diabetes patients before
and after 8 weeks of liraglutide therapy. HbA1c and body
weight were reduced following liraglutide administration (Fig-
ures 4A and 4B). This was paired with a significant expansion
in peripheral iNKT cell levels (Figure 4C). Liraglutide also signif-
icantly elevated circulating FGF21 levels (Figure 4D), which
strongly correlated with the extent of weight loss: two individ-
uals without weight loss did not display increases in FGF21,
and the individuals who lost the most weight had the largest in-Figure 3. GLP-1 Analog Liraglutide Activates iNKT Cells In Vivo and In
WT mice fed an HFD for 6–8 weeks, then injected daily with GLP-1 analog liraglu
experiment performed four times).
(A and B) (A) Circulating peripheral and (B) adipose iNKT cells levels in obese mi
(C and D) (C) Graph of activation marker CD69 and (D) intracellular cytokine stain
treatment (n = 9 per group).
(E–G) HFD-fedWT andCD1d/ (no iNKT) mice were injected daily with GLP-1 ana
(F) glucose tolerance tests and (G) total weight loss in grams (g) were measured.
(H and I) (H) Weight loss after 24 hr, and (I) from 24 hr and 120 hr after liraglutide
In (E)–(I), n = 10 per group receiving PBS, and n = 13–14 per group receiving lira
(J–M) Graphs of transcripts for (J) UCP-1, Cidea, and PGC1a; (K) FGF21; (L) FGFR
and CD1d/ mice that received PBS or liraglutide for 5 days. n = 3 per group p
Statistics have been calculated using a Student’s unpaired t test or ANOVAwith Tu
516 Cell Metabolism 24, 510–519, September 13, 2016creases in FGF21 (Figure 4E). These data demonstrate that lir-
aglutide expands iNKT cell number and increases FGF21 levels
in obese humans, consistent with our findings in high-fat-fed
mice.
Our data provide a mechanism whereby iNKT cells, by adop-
tive transfer or activation with their specific ligand aGalCer,
induce rapid and robust weight loss. Our study shows that an
innate T cell population, resident in adipose tissue, drives ther-
mogenesis and weight loss. Thus, iNKT cells join the list of other
immune cells that have been reported to control weight, namely
ILC2s (Brestoff et al., 2015; Lee et al., 2015) and macrophages
(Nguyen et al., 2011). iNKT cell actions are distinct from
those previously published. ILC2 cell production of methionine-
enkephalin peptides drove UCP1 expression and thermogenesis
in WAT (Brestoff et al., 2015), while macrophages can produce
catecholamines to sustain thermogenesis in cold temperatures
(Nguyen et al., 2011). Here we show that iNKT activation drives
production of FGF21 by adipocytes in WAT and a robust and
sustained reduction in RER, indicating b-oxidation, coupled
with UCP-1 expression, leading to thermogenic weight loss
without affecting appetite. We also show that this pathway
plays a role in another setting: liraglutide-induced weight loss.
Although this pathway is not the main mechanism of liraglutide
action, which is primarily satiety, our results highlight a role for
activation of this iNKT-FGF21 pathway in the maximal weight
loss effects of liraglutide in mice. Of additional relevance, the ac-
tions of liraglutide to induce FGF-21 and adiponectin also
required a functional iNKT cell axis. Unlike other pathways of
cytokine-driven activation of immune cells, iNKT cells can be
specifically targeted in the clinic by aGalCer and related lipid
ligand administration. aGalCer has been given to patients in
several different clinical trials for cancer and has been proven
safe and capable of activating human iNKT cells in vivo, with
minimal side effects. This study suggests that targeting iNKT
cells with specific ligands could represent a new therapeutic
approach for subjects with metabolic disorders, such as non-
alcoholic fatty liver disease or insulin resistance, that are sensi-
tive to the actions of metabolic mediators such as adiponectin
and FGF-21.EXPERIMENTAL PROCEDURES
Patients
Details of patient collection are in the Supplemental Experimental Procedures.
Bloodwas collected from ten type 2 diabetes patients before and after 8weeks
of GLP-1 analog therapy (0.6mg once daily for 2 weeks, then 1.2mg once dailyVitro
tide (50 mg/kg intraperitoneally) for 5 days (n = 5 per treatment per experiment;
ce after liraglutide treatment in vivo (n = 8–9 per group).
ing of IL-10 on adipose iNKT cells from obese WT mice post-PBS or liraglutide
log liraglutide (50 mg/kg intraperitoneally) for 5 days and (E) fasting glucose and
treatment.
glutide.
and b-klotho (KLB); and (M) adiponectin in inguinal adipose tissue of obeseWT
er experiment, repeated three times. Graphs show the mean (± SEM).
key post hoc test for groups of three or more. *p < 0.05, **p < 0.01, ***p < 0.001.
Figure 4. Liraglutide Activates Human iNKT
Cells In Vivo and Induces FGF21
Obese patients with newly diagnosed type 2 dia-
betes received daily injections of liraglutide for
8 weeks, and peripheral blood was collected
before and after.
(A–C) Change in (A) HbA1c (n = 8) and (B) body
weight (n = 10) and (C) circulating iNKT cell levels in
obese patients after 8 weeks of liraglutide therapy,
with age-matched lean controls for comparison
(n = 6).
(D and E) (D) Serum FGF21 concentration and
(E) correlation between weight loss and change
in FGF21 concentration in patients, before and
after 8 weeks of liraglutide therapy. Each symbol
represents one individual.
Statistical comparisons using Mann-Whitney
U test and paired t tests. *p < 0.05, **p% 0.01.by i.p. injection), and metabolic status, iNKT, and FGF21 levels were
measured. Informed consent was obtained from all participants, and approval
to conduct this study was obtained from the St. Vincent’s Healthcare Group
Ethics and Medical Research Committee.
Mice
Details of mouse strains are in the Supplemental Experimental Procedures.
C57BL/6 mice were purchased from Jackson Laboratory. CD1d/ and
Ja18/ were provided by Mark Exley (Harvard). FGF21 null mice were kindly
provided by Eli Lily (Badman et al., 2009). All animal work was approved by and
in compliancewith the Institutional Animal Care andUse Committee guidelines
of the Dana Farber Cancer Institute and Harvard Medical School.
Mouse Manipulations
Details of cell isolation and flow cytometry can be found in the Supplemental
Experimental Procedures. iNKT cells were measured using aGalCer analog
PBS-57-loaded or empty CD1d tetramers provided by the NIH tetramer facil-
ity. For in vivo treatment, mice were injected intraperitoneally with a single
injection of aGalCer or vehicle in 150 mL volume. For liraglutide treatment,
mice received daily injection of GLP-1 analog (50 mg/kg intraperitoneally) for
5 days. For CLAMS analysis, mice were singly housed and acclimated, then
administered vehicle control, monitored for 70 hr, given 1 mg aGalCer in
150 mL intraperitoneally, and monitored for a further 70 hr.
Statistics
The changes of outcomes between baseline and the follow-up were evaluated
using paired t tests. The difference between treatment groups was tested us-
ing unpaired two-sample t tests with Welsh’s correction for unequal variancesand one-way ANOVA followed by Tukey’s post hoc test. p% 0.05 was consid-
ered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.cmet.2016.08.003.
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